

**A Case of Transverse Myelitis Associated with
Systemic Lupus Erythematosus**

Chang Gyun Seo, M.D., Sang Hyon Kim, M.D., Seung Hyun Lee, M.D.,
Tae Sung Yun, M.D., Jae Ho Park, M.D., Jeong Geun Lim, M.D.*

Departments of Internal Medicine and Neurology,
Keimyung University School of Medicine, Taegu, Korea*

Abstract : Systemic lupus erythematosus (SLE) is an autoimmune disease associated with variable symptoms in many organs. Involvement of central nervous system in SLE is a relatively common complication. However, transverse myelitis is a rare and late complication of SLE and its prognosis is very poor, resulting in death or severe neurologic sequelae. We report a case of transverse myelitis who was diagnosed as SLE before the onset of neurologic symptoms. Transverse myelitis was diagnosed, based on the clinical presentation and MRI findings. This patient indicated that transverse myelitis could be a relatively early manifestation of SLE. We treated the patient with pulse methyprednisolone followed by cyclophosphamide, However, the treatment did not improve clinical condition of the patient.

Key Words : Systemic lupus erythematosus, Transverse myelitis

(systemic lupus ery-
thematosus, SLE) 가 가

[1].
(transverse myelitis)

, SLE, 5
 가
 [2]. SLE 13.5 g/dL,
 가 SLE 1.5-2 3,540 /mm³, 356,000
 2 /mm³, 40 mm/hr CRP
 % [3,4] SLE 0.34 g/dL
 가 [5,6]. 9.1 mg/dL, 4.2 mg/dL, ALP 112 IU/L,
 [7-9]. AST 22 IU/L, ALT 26 IU/L
 SLE 4 C₃/C₄ 60.9/22.2
 1 mg/dL M
 810.5 mg/dL 가 가
 (1:640, peripheral) ,
 dsDNA (11.98 IU/mg, : 7.0
 IU/mg) . Ro , La
 , Scl-70 , centromere ,
 36 RNP , Sm , cardiolipin
 (lupus anticoagulant)
 . 9
 ,
 , 3
 . 4 5 T2
 SLE 5 (Fig. 1).
 prednisolone
 . 3 SLE ,
 . 2 Methylprednisolone 1000 mg/day 4
 . 3 , cyclophos-
 phamide 1000 mg/day
 prednisolone 1 mg/kg/day

110/80
 mmHg, 100 / , 20 / ,
 36.8



Fig. 1. MR imaging of the T-L spine reveals long segmental high signal intensity lesion in thoracic spinal cord on T2WI with subtle enhancement on gadolinium enhancement. There are no demonstrable destructive bony structures.

[10,11]. SLE 가 가 T2 [13]. 3 - 5 (anti-phospholipid antibody) 가 가 [10]. [12]. 가 가 . Boumpas [14] SLE

가 , .

2

(multiple sclerosis) 가 oligoclonal band가 , ,

가 .

SLE . Propper Bucknall[15] 26 10 , 4 .

. Warren Kredich[16] , Lopez [17] cyclophosphamide . , cyclophosphamide, cyclophosphamide prednisolone .

(SLE) 가 , , SLE, , SLE 가 SLE 1.5-2% 2 가 . SLE 4 1

1. Fauci AS, Braunwald E, Isselbacher KT, Wilson JD, Martin JB, Kasper DL, et al. *Harrison's Principles of Internal Medicine*. in Bevera HH. *Systemic Lupus Erythematosus*. 14th ed. New York: McGraw-Hill; 1997, p.1874-88.
2. Linssen WH, Fiselier TJ, Gabreels FJ, Wevers RA, Cuppen MP, Rotteveel JJ. Acute transverse myelopathy as the initial manifestation of probable systemic lupus erythematosus in a child. *Neuropediatrics* 1988; **19**: 212-5.
3. Barile L, Lavallo C. Transverse myelitis in systemic lupus erythematosus: the effect of IV pulse methylprednisolone and cyclophosphamide. *J Rheumatol* 1992; **19**: 370-2.
4. Harisdangkul V, Doorenbos D, Subramony SH. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. *J Neurol* 1995; **242**: 326-31.
5. , , , . 1 . 1998; **41**: 326-31.
6. , , , , . 1 . 2000; **7**: 263-7.
7. Sands ML, Ryczak M, Brown RB. Recurrent aseptic meningitis followed by transverse myelitis as a presentation of systemic lupus erythematosus. *J Rheumatol* 1988; **15**: 862-4.
8. Tola MR, Granieri E, Caniatti L, Paolino E, Monetti C, Dovigo L, et al. Systemic lupus erythematosus presenting with neurological disorders. *J Neurol* 1992; **239**: 61-4.
9. Al-Husaini A, Jamal GA. Myelopathy as the main presenting feature of systemic lupus erythematosus.

- Eur Neurol* 1985; **24**: 94-106.
10. Klaiman MD, Miller SD. Transverse myelitis complicating systemic lupus erythematosus: treatment including hydroxychloroquine. *Am J Phys Med Rehabil* 1993; **72**: 158-61.
 11. Baca V, Sanchez-Vaca G, Martinez-Muniz I, Ramirez-Lacayo M, Lavalle C. Successful treatment of transverse myelitis in a child with systemic lupus erythematosus. *Neuropediatrics* 1996; **27**: 142-4.
 12. Chi CM, Chak SL. Acute transverse myelitis in systemic lupus erythematosus: clinical presentation, treatment, and outcome. *J Rheumatol* 1998; **25**: 467-73.
 13. Sanders KA, Khandji AG, Mohr JP. Gadolinium-MRI in acute transverse myelopathy. *Neurology* 1990; **40**: 1614-6.
 14. Boumpas DT, Patronas NJ, Dalakas MC, Hakim CA, Klippel JH, Balow JE. Acute transverse myelitis in systemic lupus erythematosus: magnetic resonance imaging and review of the literature. *J Rheumatol* 1990; **17**: 89-92.
 15. Propper DJ, Bucknall RC. Acute transverse myelopathy complicating systemic lupus erythematosus. *Ann Rheum Dis* 1989; **48**: 512-5.
 16. Warren RW, Kredich DW. Transverse myelitis and acute central nervous system manifestation of systemic lupus erythematosus. *Arthritis Rheum* 1984; **27**: 1058-60.
 17. Lopez DM, Khamashta MA, Sanchez AD, Ingles FP, Uriol PL, Agua AG. Transverse myelitis as a first manifestation of systemic lupus erythematosus: a case report. *Lupus* 1995; **4**: 239-42.